Related Experiment Video
Updated: May 4, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Should African Americans with hypertension be treated differently than non-African Americans?
John M Flack1, Brian A Ference, Phillip Levy
1Division of Translational Research and Clinical Epidemiology, Department of Medicine, Wayne State University, Detroit, MI, USA, jflack@med.wayne.edu.
Insights
Earlier hypertension treatment may prevent target organ damage and reduce cardiovascular disease (CVD) risk, especially in African Americans. Re-examining treatment paradigms is crucial for better blood pressure (BP) control and public health.
Area of Science:
- Cardiovascular Medicine
- Hypertension Research
- Public Health
Background:
- African Americans experience a disproportionately higher burden of hypertension, with more severe blood pressure (BP) elevations and greater risk for complications like stroke and heart failure compared to white populations.
- Existing hypertension treatment guidelines may not fully address the unique challenges and risks faced by diverse populations, particularly concerning optimal BP targets.
- Sub-clinical vascular injury can occur at lower BP levels in African Americans, highlighting the need for tailored treatment strategies.
Purpose of the Study:
- To evaluate the potential benefits of earlier hypertension treatment initiation across all populations.
- To explore a revised hypertension treatment paradigm that may attenuate age-related BP increases and reduce residual cardiovascular disease (CVD) risk.
- To assess the impact of such a paradigm on the high-risk African American population.
Main Methods:
- Analysis of randomized prospective data from hypertension endpoint trials.
- Examination of Mendelian randomization studies on the impact of lifelong lower systolic blood pressure (SBP) levels.
- Review of existing literature on BP control rates and clinical complications in different racial groups.
Main Results:
- Clinical trials show similar BP-lowering benefits across various pre-treatment BP levels, supporting earlier intervention.
- Mendelian randomization suggests lifelong lower SBP significantly reduces coronary heart disease (CHD) risk more than clinical trial reductions.
- Current treatment approaches leave significant residual CVD risk, indicating a need for paradigm shifts.
Conclusions:
- Re-examining the hypertension treatment paradigm is warranted, advocating for earlier intervention before target organ damage occurs.
- Earlier treatment could prevent or attenuate age-related BP rise and reduce residual CVD risk.
- A revised approach holds substantial clinical and public health benefits, especially for under-treated, high-risk African Americans.
Abstract:
African Americans have a higher burden of hypertension, more severe blood pressure (BP) elevations, more concurrent risk-enhancing co-morbidities (e.g., diabetes), sub-clinical vascular injury at lower non-hypertensive BP levels, lower BP control rates, and significantly greater risk for adverse pressure-related clinical complications (e.g., stroke, heart failure) than whites. Randomized prospective data from hypertension endpoint trials show a virtually identical percentage reduction in CVD risk for a given magnitude of BP lowering, irrespective of the presence or absence of pre-treatment CVD across a broad range of BP down to pre-treatment BP levels of 110/70 mm Hg. These data, mostly emanating from white populations, do not necessarily inform practitioners as to the level below which BP should be lowered in those with established, long-standing hypertension; however, these data do provide support for initiating hypertension treatment at lower than conventional BP thresholds. A Mendelian randomized study examining the impact of life-long lower SBP levels showed that lifelong exposure to 10 mm Hg lower SBP was associated with an 82 % lesser rate of SBP rise per decade and a 58 % lower CHD risk that was much greater than the 22 % reduction in CHD reported for the same magnitude of SBP reduction in clinical trials. Arguably, it is the hypertension treatment paradigm that merits reexamination. Earlier hypertension treatment in all populations prior to the onset of significant pressure-related target organ injury might conceivably prevent, or at least significantly attenuate, the well documented age-related rise in BP seen in most Western societies. In addition, this treatment paradigm might also reduce the significant residual CVD risk observed under the current recommended approach to hypertension treatment. This new approach to therapy would likely have substantial clinical and public health benefits in the high-risk, under-treated African American population that suffers outsized devastating consequences from inadequate control of BP.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension I: Introduction
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension and Regulation of Blood Pressure
Hypertension V: Nursing Management
Special considerations while measuring blood pressure
Monitoring Both Arms:
Monitoring BP in both arms during the initial assessment is advisable, as the systolic value may differ by five to ten mm Hg between arms. For subsequent BP assessments, use the arm with the higher reading.

